Delpharm Invests US$148 Million (CAD 200 Million) for State-of-the-Art Sterile Injectable Manufacturing Facility in Canada
Introduction:
Delpharm plans to invest US$148 million (CAD 200 million) to develop a state-of-the-art sterile injectable manufacturing facility in Boucherville, Canada.
Features:
The upcoming facility will be equipped to produce a range of sterile injectable medicines essential for hospital treatments, including those required for surgery and intensive care.
The manufacturing suite will be integrated to enhance production efficiency and support the latest advancements in sterile drug formulation.
This expansion will significantly increase the production capacity of the Boucherville site.
Furthermore, the modernisation project will introduce a dedicated facility designed to improve the aseptic processing of critical medicines, ensuring compliance with the latest Good Manufacturing Practices (GMP) guidelines.
The planned upgrades include the installation of a new filling line and dedicated cleanroom areas to support aseptic processing in line with current GMP standards.
Construction and upgrade activities are scheduled to continue until 2031, allowing for a phased implementation that minimises disruptions to ongoing production.
Specifications:
| Name | Delpharm |
| Type | New Construction |
| Budget | US$148 million (CAD 200 million) |
| Year | 2031 |
